


Considerations for Writing Specialty Pharmacy Prescriptions for LEQVIO®

When you are acquiring LEQVIO through a specialty pharmacy, it is important to ensure that the prescription is written completely and accurately. Your prescription may be rejected if it is incorrectly written.

Please see below for some considerations on how you may write the two prescriptions for LEQVIO.

This information is provided for educational purposes only. It is not meant to be exhaustive of all information that may need to be considered when writing a prescription. It is the sole responsibility of the health care provider to ensure the accuracy of all statements and information included in the prescription for an individual patient.



Prescription #1: Starter Doses (Initial and Day 90)

Dose Type	284 mg/1.5 mL (189 mg/mL) in a single-dose prefilled syringe
Quantity	1
Refill	1
Administration	<ul style="list-style-type: none"> • HCP to inject inclisiran subcutaneously into the abdomen, upper arm, or thigh • HCP to administer initially and again at 3 months

Prescription #2: Maintenance Doses (Every 6 Months)

Dose Type	284 mg/1.5 mL (189 mg/mL) in a single-dose prefilled syringe
Quantity	1
Refill	1
Administration	<ul style="list-style-type: none"> • HCP to inject inclisiran subcutaneously into the abdomen, upper arm, or thigh • HCP to administer every 6 months after the first two doses

Remember, some specialty pharmacies may accept slight variations of the prescription. It is important to contact your specialty pharmacy and confirm their guidelines for how to appropriately write a prescription for LEQVIO.

If you have additional questions, please reach out to your Novartis Access and Reimbursement Expert.

INDICATION

LEQVIO (inclisiran) injection is indicated as an adjunct to diet and exercise to reduce low-density lipoprotein cholesterol (LDL-C) in adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia (HeFH).

IMPORTANT SAFETY INFORMATION

LEQVIO is contraindicated in patients with a prior serious hypersensitivity reaction to inclisiran or any of the excipients in LEQVIO. Serious hypersensitivity reactions have included angioedema. Adverse reactions in clinical trials (≥3% of patients treated with LEQVIO and more frequently than placebo) were injection site reaction, arthralgia, and bronchitis.

Please click [here](#) for LEQVIO full Prescribing Information.

Licensed from Alnylam Pharmaceuticals, Inc.